Actinium Pharmaceuticals (ATNM) Long-Term Deferred Tax (2016 - 2023)
Actinium Pharmaceuticals (ATNM) posted quarterly Long-Term Deferred Tax of $41.7 million for Q4 2023, down 5.73% year-over-year from $44.2 million in Q4 2022, and down 5.73% quarter-over-quarter from $44.2 million in Q4 2022.
Actinium Pharmaceuticals (ATNM) Long-Term Deferred Tax (2016 - 2023) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Long-Term Deferred Tax for 8 consecutive years, with $41.7 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Long-Term Deferred Tax fell 5.73% year-over-year to $41.7 million; the TTM figure through Dec 2023 stood at $41.7 million (down 5.73% YoY), while the FY2023 annual figure was $41.7 million, down 5.73% from the prior year.
- Long-Term Deferred Tax declined to $41.7 million in Q4 2023 per ATNM's latest filing, from $44.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $44.2 million in Q4 2022 and bottomed at $31.7 million in Q4 2019.
- Historically, Long-Term Deferred Tax has averaged $37.6 million across 5 years, with a median of $36.4 million in 2021.
- Annual changes were most pronounced in 2019 — Long-Term Deferred Tax fell 8.23% — and 2022, when it increased 21.5%.
- Actinium Pharmaceuticals' Long-Term Deferred Tax stood at $31.7 million in 2019, then gained by 7.15% to $34.0 million in 2020, then increased by 7.22% to $36.4 million in 2021, then grew by 21.5% to $44.2 million in 2022, then retreated by 5.73% to $41.7 million in 2023.
- Business Quant data shows ATNM's Long-Term Deferred Tax at $41.7 million in Q4 2023, $44.2 million in Q4 2022, and $36.4 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 41.70 Mn |
| Dec 31, 2022 | 44.23 Mn |
| Dec 31, 2021 | 36.41 Mn |
| Dec 31, 2020 | 33.96 Mn |
| Dec 31, 2019 | 31.69 Mn |
| Dec 31, 2018 | 34.53 Mn |
| Dec 31, 2017 | 30.83 Mn |
| Dec 31, 2016 | 38.87 Mn |